Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Envista Holdings (NVST) and Hologic (HOLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Blueprint Medicines (BPMC – Research Report), Envista Holdings (NVST – Research Report) and Hologic (HOLX – Research Report).

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Blueprint Medicines (BPMC)

In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Blueprint Medicines, with a price target of $130.00. The company’s shares closed last Thursday at $99.25.

According to TipRanks.com, Cheng is ranked 0 out of 5 stars with an average return of -24.3% and a 27.6% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Protagonist Therapeutics, and Intellia Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Blueprint Medicines with a $130.19 average price target, a 42.8% upside from current levels. In a report issued on April 16, Wedbush also maintained a Buy rating on the stock with a $128.00 price target.

See the top stocks recommended by analysts >>

Envista Holdings (NVST)

In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Hold rating on Envista Holdings, with a price target of $17.00. The company’s shares closed last Thursday at $16.34, close to its 52-week low of $15.15.

According to TipRanks.com, Vatnsdal is a 1-star analyst with an average return of -3.1% and a 38.0% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Twist Bioscience, and Guardant Health. ;'>

Envista Holdings has an analyst consensus of Hold, with a price target consensus of $20.09, which is a 22.6% upside from current levels. In a report issued on April 30, Piper Sandler also maintained a Hold rating on the stock with a $17.00 price target.

Hologic (HOLX)

William Blair analyst Andrew Brackmann reiterated a Buy rating on Hologic today. The company’s shares closed last Thursday at $57.28.

According to TipRanks.com, Brackmann is a 1-star analyst with an average return of -7.2% and a 33.3% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Butterfly Network, and Quest Diagnostics. ;'>

Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $77.50, a 34.7% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a $70.00 price target.

Read More on BPMC:

Disclaimer & DisclosureReport an Issue

• Blueprint Medicines: Strong Market Position and Growth Potential Justify Buy Rating with $135 Price Target
• Blueprint Medicines Reports Strong Q1 2025 Growth
• Blueprint Medicines Corp. Reports Strong Earnings Growth
• Positive Outlook for Blueprint Medicines Driven by Strong Ayvakit Performance and Pipeline Progress
• Blueprint Medicines: Strong Financial Performance and Strategic Initiatives Justify Buy Rating